Supplement for Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Supplemental material for the Bissonnette et al. Tapinarof Cream ADORING 3 Phase 3 Long-term Trial in AD article